Socialiya - Entertainment. Knowledge. Community.
Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout

The acquisition of Soleno and its hyperphagia drug Vykat XR comes a few months after Neurocrine unve...

BUSINESS NEWS April 06, 2026

Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout

The acquisition of Soleno and its hyperphagia drug Vykat XR comes a few months after Neurocrine unveiled an obesity pipeline.

24 views 0 likes 0 comments
Share:
The acquisition of Soleno and its hyperphagia drug Vykat XR comes a few months after Neurocrine unveiled an obesity pipeline.

Author: Fierce Pharma

Read Original Article

Related News

Advertisement
APNA POS
Advertisement
socialiya
Advertisement

Top Categories

Advertisement
APNA POS
Advertisement
socialiya
Advertisement
socialiya
Advertisement
APNA POS